Sinovac Biotech Ltd (SVA) Quote

https://hengreninvestment.com/sinovac-fairness/

Sinovac Fairness
For six years we Sinovac shareholders have been frustrated by management actions that left us unable to benefit from a historic bull run in vaccine stocks during the COVID-19 pandemic.

Now the new board has an opportunity to correct this by distributing Sinovac's excessive cash of more than $10 billion with whom the cash belongs - we shareholders.

Join us to insist Sinovac's board do the right thing and return the cash to its rightful owners to compensate for this epic missed opportunity.

https://www.nasdaq.com/press-release/heng-ren-partners-calls-sinovac-disclose-record-and-payment-dates-special-dividend

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
Published
Apr 10, 2025 3:44pm EDT

BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025. More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed. Heng Ren previously sent the Board a letter on March 19, and received no response. The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than sufficient for Sinovac's operating needs. Heng Ren encourages like-minded shareholders to visit https://www.hengreninvestment.com/sinovac-fairness/ and contact Sinovac directly.

Tender offer for Sinovac Shares:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/0001870412-24-000001-index.htm

Investor Letter:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/Exhibit_A3.htm

For investors that are sick of holding the shares, this might be a good opportunity to exit.

Annual reports and other public disclosures from the company are available here:

https://www.sec.gov/edgar/browse/?CIK=0001084201

https://www.otcmarkets.com/stock/SVA

https://www.otcmarkets.com/stock/SVA

https://www.otcmarkets.com/stock/SVA

https://www.otcmarkets.com/stock/SVA

imo... i guarantee my following will destroy this ticker....quickly...SVA

IHuser

imo... ya mick me and my boys own this market now.....gl...wont be a market soon~



IHuser

https://www.otcmarkets.com/stock/SVA

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

Date

Event

January 28, 2020

SINOVAC established and launched a new COVID-19 vaccine research and development project

June 13, 2020

SINOVAC announced a Phase I/II clinical study of its new COVID-19 vaccine, showing the vaccine was safe and effective in producing neutralizing antibodies

February 16, 2021

Professor Lau Chak-sing, Convener of the Hong Kong Vaccine Advisory Expert Committee, announced the committee’s review of data for CoronaVac®. Results showed CoronaVac® benefits outweigh the risks. The committee recommended the vaccine to the government

February 19, 2021

Within 72 hours after the advisory committee's recommendation, the first batch of one million doses of CoronaVac® arrived in Hong Kong from Beijing. Hong Kong subsequently launched a large-scale COVID-19 vaccination program

June 2, 2022

CoronaVac® was validated by the World Health Organization’s Emergency Use List Procedure

February 20, 2022

SINOVAC Foundation donations to Hong Kong helped local communities in the fight against the COVID-19 pandemic

April 14, 2022

In cooperation with HKU and Gleneagles Hospital, SINOVAC’s inactivated COVID-19 vaccine (omicron variant) was approved for clinical trials in Hong Kong

August 4, 2022

Children between the ages of 6 months and 3 years old were eligible for receiving CoronaVac®. To help the public complete their vaccinations as soon as possible, Hong Kong had opened up multiple new vaccination centers.

December 16, 2022

CoronaVac® was fully registered in Hong Kong under the Pharmacy and Poisons Ordinance Cap 138. It is one of the first COVID-19 vaccines approved for official registration in Hong Kong

May 10, 2023

SINOVAC announced the supply of the inactivated COVID-19 vaccine CoronaVac® (original strain) to Hong Kong’s private market, with plans to donate free COVID-19 vaccines to children

[1] HKSAR news.gov.hk: Professor Lo Chung Mo’s Chinese article dated 15 Sept 2022. https://www.news.gov.hk/chi/2022/09/20220915/20220915_145920_647.html

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.



View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005485/en/

Sinovac Biotech Ltd.
PR Team
pr@sinovac.com

decrease in sales <> https://www.otcmarkets.com/filing/html?id=16605858&guid=_1T-knRCUJRXB3h

interesting review <> https://ih.advfn.com/stock-market/NASDAQ/sinovac-biotech-SVA/stock-news/91160230/amended-statement-of-beneficial-ownership-sc-13d-a

$SVA

Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 05/25/2023 11:14:28 AM
CoronaVac® von SINOVAC erfüllt Hongkongs Bedarf an COVID-19-Impfstoffen zur Selbstzahlung • Business Wire • 05/12/2023 04:22:00 PM
??????CoronaVac ®????????????COVID-19????????????????? • Business Wire • 05/10/2023 06:02:00 PM
Le vaccin CoronaVac® de SINOVAC répond au besoin pour des vaccins contre la COVID-19 autopayés à Hong Kong • Business Wire • 05/10/2023 06:02:00 PM

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM

Recent SVA News
???????????????? • Business Wire • 02/23/2023 12:38:00 PM
Sinovac modifie le régime de droits des actionnaires • Business Wire • 02/22/2023 05:02:00 PM
Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

$SVA http://www.sinovac.com/

SINOVAC Reports Unaudited First Half of 2022 Financial ResultsBUSINESS WIRE | 12/29/2022

FORM TYPE RECEIVED PERIOD END DATE REPORT
6-K 12/29/2022 12/29/2022 PDFRTFHTMLXLS
SC 13D/A 12/12/2022 PDFRTFHTMLXLS
6-K 11/04/2022 11/04/2022 PDFRTFHTML
6-K 06/09/2022 06/09/2022 PDFRTFHTML
6-K 05/06/2022 05/06/2022 PDFRTFHTML
6-K 05/02/2022 04/29/2022 PDFRTFHTMLXLS
20-F 04/29/2022 12/31/2021 PDFRTFHTMLXLS
8-A12B/A 02/22/2022 PDFRTFHTMLXLS
6-K 02/22/2022 02/22/2022 PDFRTFHTML
6-K 12/30/2021 12/30/2021 PDFRTFHTMLXLS

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

SVA Latest News
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/29/2022 08:41:47 AM
SINOVAC Reports Unaudited First Half of 2022 Financial Results 12/29/2022 08:30:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) 12/12/2022 06:45:09 AM
?????????????WHO???????? 11/04/2022 08:01:00 AM

https://www.otcmarkets.com/stock/SVA/security

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

https://www.otcmarkets.com/stock/SVA/disclosure

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link
Turkey signed a deal with Sinovac for 50 million doses of the vaccine. The first three million doses are scheduled to arrive Monday in Turkey,
Mr. Koca said. Mr. Koca said Turkey would also get 4.5 million doses of the Pfizer-BioNTech vaccine by the end of March.
Around 1 million doses are expected to arrive at the end of January, he said.

Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com

Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com

http://www.sinovac@sinovac.com

http://www.pr@sinovac.com

Recent SVA News
??????COVID-19??????????6????????????????? • Business Wire • 08/05/2022 06:19:00 PM
L'utilisation du vaccin anti-COVID-19 de SINOVAC approuvée à partir de l'âge de six mois à Hong Kong • Business Wire • 08/03/2022 04:45:00 PM
COVID-19-Impfstoff von SINOVAC in Hongkong zur Verwendung bei Kindern ab einem Alter von 6 Monaten zugelassen • Business Wire • 08/03/2022 04:45:00 PM
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong • Business Wire • 08/03/2022 10:00:00 AM
?????????4???????????????????? • Business Wire • 07/20/2022 12:00:00 PM
SINOVAC startet klinische Studie für seinen Vierfach-Grippeimpfstoff in Chile • Business Wire • 07/19/2022 01:31:00 PM
SINOVAC lance un essai clinique au Chili pour son vaccin antigrippal quadrivalent • Business Wire • 07/19/2022 11:16:00 AM

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.00
SVA Detailed Quote

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.10
SVA Detailed Quote

https://www.otcmarkets.com/stock/SVA/overview

https://www.otcmarkets.com/stock/SVA/overview

never answered e-mail $SVA

yes hope it does $SVA

$SVA News: COVID-19-Impfstoff von SINOVAC erhält in Brasilien Notfallzulassung für Kinder im Alter von 3 bis 5 Jahren 07/14/2022 01:36:00 PM
SVA News: Le vaccin SINOVAC contre le COVID-19 est autorisé pour une utilisation d’urgence chez les enfants âgés de 3 à 5 ans au Brésil 07/14/2022 01:00:00 PM